| GlaxoSmithKline Services Unlimited v Commission | |
|---|---|
 The logo of GlaxoSmithKline | |
| Court | European Court of Justice |
| Citation(s) | (2009) C-513/06, [2006] ECR II-2969 |
| Keywords | |
| Competition, collusion | |
GlaxoSmithKline Services Unlimited v Commission (2009) C-513/06 is an EU competition law case, concerning the meaning of harm to "competition" under TFEU article 101.
GlaxoSmithKline put a clause in contracts with Spanish wholesalers requiring they did not export medicines to other Member States. National health authorities fix prices for medicines at different levels, and it wished to prevent wholesalers shipping cheap drugs from Spain to the UK. The Commission found that GSK's agreement had the object of restricting competition, given that the agreement served to partition the internal market. GSK appealed against the finding.
The General Court held that the prevention of parallel trade was not enough to amount to a restriction of competition. It said that the objective of article 101 is to stop ‘reducing the welfare of the final consumer of the products in question.' The Commission must not only find a reduction of parallel trade, but also say why this damages competition. [1]
The Court of Justice overturned the General Court, and held that prevention of parallel imports was unlawful. The General Court had committed an error of law by holding that some effect on consumers was necessary. The unlawfulness of this activity had been established in Consten and Grundig . The Court said the following. [2]
63. [...] it must be borne in mind that the Court has held that, like other competition rules laid down in the Treaty, Article 85 aims to protect not only the interests of competitors or of consumers, but also the structure of the market and, in so doing, competition as such. Consequently, for a finding that an agreement has an anti-competitive object, it is not necessary that final consumers be deprived of the advantages of effective competition in terms of supply or price.
In the United States, antitrust law is a collection of mostly federal laws that regulate the conduct and organization of businesses to promote competition and prevent unjustified monopolies. The three main U.S. antitrust statutes are the Sherman Act of 1890, the Clayton Act of 1914, and the Federal Trade Commission Act of 1914. These acts serve three major functions. First, Section 1 of the Sherman Act prohibits price fixing and the operation of cartels, and prohibits other collusive practices that unreasonably restrain trade. Second, Section 7 of the Clayton Act restricts the mergers and acquisitions of organizations that may substantially lessen competition or tend to create a monopoly. Third, Section 2 of the Sherman Act prohibits monopolization.
Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of British origin, it was produced by British pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.
European Union competition law is the competition law in use within the European Union. It promotes the maintenance of competition within the European Single Market by regulating anti-competitive conduct by companies to ensure that they do not create cartels and monopolies that would damage the interests of society.
Competition law is the field of law that promotes or seeks to maintain market competition by regulating anti-competitive conduct by companies. Competition law is implemented through public and private enforcement. It is also known as antitrust law, anti-monopoly law, and trade practices law; the act of pushing for antitrust measures or attacking monopolistic companies is commonly known as trust busting.
A vertical agreement is a term used in competition law to denote agreements between firms at different levels of a supply chain. For instance, a manufacturer of consumer electronics might have a vertical agreement with a retailer according to which the latter would promote their products in return for lower prices. Franchising is a form of vertical agreement, and under European Union competition law this falls within the scope of Article 101.
Article 101 of the Treaty on the Functioning of the European Union prohibits cartels and other agreements that could disrupt free competition in the European Economic Area's internal market.
Article 102 of the Treaty on the Functioning of the European Union (TFEU) is aimed at preventing businesses in an industry from abusing their positions by colluding to fix prices or taking action to prevent new businesses from gaining a foothold in the industry. Its core role is the regulation of monopolies, which restrict competition in private industry and produce worse outcomes for consumers and society. It is the second key provision, after Article 101, in European Union (EU) competition law.
Sir Andrew Philip Witty is a British business executive, who is the current chief executive officer (CEO) of UnitedHealth Group. He was also the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.
United Kingdom competition law is affected by both British and European elements. The Competition Act 1998 and the Enterprise Act 2002 are the most important statutes for cases with a purely national dimension. However, if the effect of a business' conduct would reach across borders, the European Commission has competence to deal with the problems, and exclusively EU law would apply. Even so, the section 60 of the Competition Act 1998 provides that UK rules are to be applied in line with European jurisprudence. Like all competition law, that in the UK has three main tasks.
Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).
Canada v GlaxoSmithKline Inc is the first ruling of the Supreme Court of Canada that deals with issues involving transfer pricing and how they are treated under the Income Tax Act of Canada ("ITA").
Commission v Anic Partecipazioni SpA (1999) C-49/92 is an EU competition law case, concerning the requirements for finding that there has been a cartel, or unlawful collusion, within TFEU article 101.
Consten SaRL and Grundig GmbH v Commission (1966) Case 56/64 is an EU competition law case, concerning vertical anti-competitive agreements.
Bundesverband der Arzneimittel-Importeure eV and Commission v Bayer (2004) C-2/01 is an EU competition law case, concerning the boundaries of unlawful collusion.
T-Mobile Netherlands BV v Raad van bestuur van de Nederlandse Mededingingsautoriteit (2009) C-8/08 is an EU competition law case, concerning the requirements for finding that firms have colluded with the "object" of harming competition.
O2 (Germany) GmbH & Co OHG v Commission (2006) T-328/03 is an EU competition law case, concerning the requirements for a restriction of competition to be found under TFEU article 101.
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.
A hub-and-spoke conspiracy is a legal construct or doctrine of United States antitrust and criminal law. In such a conspiracy, several parties ("spokes") enter into an unlawful agreement with a leading party ("hub"). The United States Court of Appeals for the First Circuit explained the concept in these terms:
In a "hub-and-spoke conspiracy," a central mastermind, or "hub," controls numerous "spokes," or secondary co-conspirators. These co-conspirators participate in independent transactions with the individual or group of individuals at the "hub" that collectively further a single, illegal enterprise.
Mergers in United Kingdom law is a theory-based regulation that helps forecast and avoid abuse, while indirectly maintaining a competitive framework within the market. A true merger is one in which two separate entities merge into an entirely new entity. In Law the term ‘merger’ has a much broader application, for example where A acquires all, or a majority of, the shares in B, and is able to control the affairs of B as such.